GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Additional Paid-In Capital

Alphamab Oncology (HKSE:09966) Additional Paid-In Capital : HK$4,432.8 Mil(As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology Additional Paid-In Capital?


Alphamab Oncology's quarterly additional paid-in capital increased from Dec. 2022 (HK$4,160.7 Mil) to Jun. 2023 (HK$4,433.6 Mil) but then stayed the same from Jun. 2023 (HK$4,433.6 Mil) to Dec. 2023 (HK$4,432.8 Mil).

Alphamab Oncology's annual additional paid-in capital declined from Dec. 2021 (HK$4,551.0 Mil) to Dec. 2022 (HK$4,160.7 Mil) but then increased from Dec. 2022 (HK$4,160.7 Mil) to Dec. 2023 (HK$4,432.8 Mil).

Alphamab Oncology Additional Paid-In Capital Historical Data

The historical data trend for Alphamab Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology Additional Paid-In Capital Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial - - 4,551.05 4,160.74 4,432.75

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,551.05 - 4,160.74 4,433.60 4,432.75

Alphamab Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Alphamab Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology (HKSE:09966) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (HKSE:09966) » Definitions » Additional Paid-In Capital
Comparable Companies
HKSE:06660 HKSE:01541 HKSE:09969 HKSE:01952 HKSE:02315 HKSE:06955 HKSE:02105 HKSE:06855 HKSE:02480 HKSE:02696 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
3NK:Germany
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215024
Website
https://www.alphamabonc.com
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in discovery, development manufacturing and commercialization of biotherapeutics for cancer treatment.

Alphamab Oncology (HKSE:09966) Headlines

No Headlines